165 results on '"Allez, Matthieu"'
Search Results
2. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
3. Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease
4. A CEACAM5-derived Peptide Activating CD8+ Regulatory T Cells: A Future Option for Restoring Mucosal Homeostasis in Crohn’s Disease?
5. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease
6. Safety and Efficacy of Antigen-Specific Regulatory T-Cell Therapy for Patients With Refractory Crohn's Disease
7. Su1513: IMPACT OF MODERATE-TO-SEVERE ENDOSCOPIC DISEASE CRITERIA ON ENDOSCOPIC RESPONSE, ENDOSCOPIC REMISSION, AND DEEP REMISSION IN PATIENTS RECEIVING USTEKINUMAB OR ADALIMUMAB IN THE SEAVUE STUDY
8. Tu1445: EFFECT OF PHARMACOKINETICS AND IMMUNOGENICITY ON CLINICAL AND ENDOSCOPIC EFFICACY IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SEAVUE STUDY
9. 99: IDENTIFICATION AND CHARACTERIZATION OF T-CELL RECEPTOR SEQUENCES ASSOCIATED WITH CROHN'S DISEASE
10. Tu1545: TRANS-CONTINENTAL ANALYSIS OF OVER 2,000 INFLAMMATORY BOWEL DISEASE PATIENTS IMPLICATES GEOGRAPHY, DISEASE TYPE, AND EXPOSURE TO IMMUNOSUPPRESSION AS DRIVERS OF SARS-COV-2 SEROPREVALENCE
11. Su1499: IMMUNOMODULATORS ARE PROTECTIVE AGAINST SEVERE COVID 19: RESULTS FROM A LARGE MULTICENTRE COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
12. Mo1126: EPIGENETIC MASTER REGULATORS HDAC1 AND HDAC5 CONTROL PATHOBIONT ENTEROBACTERIA COLONIZATION IN ILEAL MUCOSA OF CROHN'S DISEASE PATIENTS
13. Tu1497: COMPARISON OF THE RISK OF CLINICAL RECURRENCE AFTER ILEOCOLONIC RESECTION FOR CROHN'S DISEASE FOR MODIFIED RUTGEERTS’ SCORE I2A AND I2B CATEGORIES: INDIVIDUAL PATIENT DATA META-ANALYSIS.
14. Tu1508: EFFICACY AND SAFETY OF INDUCTION THERAPY WITH CALCINEURIN INHIBITORS IN COMBINATION WITH USTEKINUMAN FOR ACUTE SEVERE COLITIS
15. 608: DIET CONTROLS SEGMENTED FILAMENTOUS BACTERIA IN DRIVING CROHN'S DISEASE-LIKE INFLAMMATION IN TNFΔARE MICE
16. 215: MITOCHONDRIAL PERTURBATION OF THE EPITHELIUM CAUSES MICROBIAL DYSBIOSIS AND UNRESOLVED TISSUE INJURY IN INTESTINAL INFLAMMATION
17. Su1490: COVID-19: A PREVALENCE RATE TWO TIMES LOWER THAN THAT OF THE GENERAL POPULATION IN FRENCH PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH INTRAVENOUS BIOLOGIC AGENTS
18. 465: ROLE OF ADHERENT AND INVASIVE E. COLI IN CROHN'S DISEASE: LESSONS FROM THE POSTOPERATIVE RECURRENCE MODEL
19. 1179 PERSISTENCE, EFFICACY AND TOLERANCE OF SUBCUTANEOUS INFLIXIMAB AFTER SWITCH FROM INTRAVENOUS INFLIXIMAB IN IBD PATIENTS IN REMISSION:: ONE-TEAR RESULTS FROM A MULTICENTER PROSPECTIVE COHORT
20. Mo1770 INTEROBSERVER AGREEMENT OF CURRENT AND NEW PROPOSED ENDOSCOPIC SCORES FOR POSTOPERATIVE RECURRENCE IN CROHN'S DISEASE
21. Su1743 GUSELKUMAB BINDING TO CD64+ IL-23–PRODUCING MYELOID CELLS ENHANCES POTENCY FOR NEUTRALIZING IL-23 SIGNALING
22. 775d Ustekinumab Versus Adalimumab for Induction and Maintenance Therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE Study
23. Challenges and Opportunities in IBD Clinical Trial Design
24. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies
25. Sa554 CHRONIC POUCHITIS AND CROHN'S DISEASE OF THE POUCH AFTER ILEAL POUCH-ANAL ANASTOMOSIS : INCIDENCE AND RISK FACTORS
26. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD
27. 1254a ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
28. Tu1768 PERSISTENCE OF SUBCUTANEOUS INFLIXIMAB AFTER SWITCHING FROM INTRAVENOUS IN A FRENCH NATIONAL COHORT OF IBD PATIENTS IN REMISSION
29. Tu1731 EFFICACY OF ETRASIMOD ON SYMPTOMATIC RELIEF IN PATIENTS WITH ULCERATIVE COLITIS: AN ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
30. 1150 METABOLIC INJURY OF THE INTESTINAL EPITHELIUM TRIGGERS DYSBIOTIC EXPANSION OF BACTEROIDES SPP. DRIVING CHRONIC INFLAMMATION
31. 769 GUSELKUMAB, AN IL-23P19 SUBUNIT-SPECIFIC MONOCLONAL ANTIBODY, BINDS CD64+ MYELOID CELLS AND POTENTLY NEUTRALIZES IL-23 PRODUCED FROM THE SAME CELLS
32. Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting
33. 946 DEEP REMISSION AT 1 YEAR IS NOT ASSOCIATED WITH BETTER OUTCOME IN CROHN'S DISEASE: LONG-TERM DATA FROM TAILORIX
34. The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells
35. 258 – Integrated Metabolomic and Microbiome Approach Revealed Functional Signatures Associated with Disease Severity in Inflammatory Bowel Disease
36. 120 – Mitochondrial Impairment in Crohn's Disease-Like Inflammation Drives Intestinal Stem Cell Transition Towards Dysfunctional Paneth Cells
37. 365 – Efficacy and Safety of Infliximab Retreatment in Luminal Crohn's Disease: A Multicentre, Prospective, Observational Cohort (Regain) Study
38. Su1798 - Comparison Between Faecal Chitinase 3-Like 1, Matrix Metalloprotease 9 and Calprotectin to Assess Mucosal Healing in Patients with Crohn's Disease: A Multicenter Prospective Study
39. 278 - Sialic Acid: A Possible Antigenic Epitope in the Generation of Antibodies to Infliximab (ATI)
40. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn’s Disease
41. Anti-TNF for Post-Operative Prevention in Crohn's Disease: The Detection of Anti-Drug Antibodies at Time of Surgery is Associated with an Increased Risk of Endoscopic Recurrence
42. Identification of Disease-Relevant Bacterial Signatures in Gnotobiotic IL-10 Deficient Mice using Fecal Samples from IBD Patients Undergoing Hematopoietic Stem Cell Transplantation
43. The Presence of Adherent-Invasive Escherichia Coli (AIEC) on the Surgical Specimen is a Predictor of Severe Endoscopic Postoperative Recurrence in Ileal Crohn's Disease
44. Efficacy of Vedolizumab on Extraintestinal Manifestation in Patients with Inflammatory Bowel Diseases: A Post-Hoc Analysis of the Observ-IBD Cohort of the Getaid
45. Pilot Study: Selective Deglycosylation of Terminal Sialic Acid on Infliximab Increases Binding of Antibodies to Infliximab (ATI) in ATI-Positive Inflammatory Bowel Disease (IBD) Patients
46. Hydrocortisone Premedication Withdrawal in Patients on Stable Infliximab Maintenance: Clinical and Pharmacokinetic Outcomes
47. Resetting of the Mucosal T Cell Repertoire after Hematopoietic Stem Cell Transplantation in Refractory Crohn’s Disease
48. 385 Impact of an Education Program on IBD Patient's Skills: One Year Results of the ECIPE Randomized, Controlled Multicenter Study
49. 991 Prediction of Clinical and Endoscopic Remission After Autologous Stem Cell Transplantation in Treatment Refractory Crohn's Disease: Pooled Results From the ASTIC Trial
50. 692 Drug-Level Based Dosing Versus Symptom-Based Dose Adaptation in Patients With Crohn's Disease: A Prospective, Randomized Multicenter Study (TAILORIX)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.